John F. Witherspoon, who passed away September 25, 2026, had a stellar career in patent law that spanned more than 50 years. He was devoted to private law practice, government service, and law school teaching. He was a beloved mentor to countless students and younger lawyers and an inspiration to all who knew him.
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a decision Friday in Pioneer Hi-Bred International, Inc. v. Inari Agriculture, Inc. affirming a Patent Trial and Appeal Board (PTAB) final written decision that found claims 1 through 33 of a patent on herbicide-degrading enzymes unpatentable for lack of enablement. The CAFC rejected arguments that the PTAB improperly relied on experimental data generated after the patent’s priority date and abused its discretion in crediting an expert witness.
Congress has been holding hearings on pharmaceutical patents and drug prices, along with U.S. Patent and Trademark Office (USPTO) fee-setting and oversight. During these hearings, America’s pharmaceutical innovators face an unusual criticism: They are accused of abusing the patent system not only when they invent new medicines, but also when they improve them.
This week in Other Barks & Bites: the Federal Circuit affirms the invalidation of twist drill patent claims because the challenged patent could not claim priority to a parent patent application qualifying as prior art; the Third Circuit unseals its ruling against ROSS Intelligence’s fair use defense indicating some limitations to the decision’s holding in the generative AI context;
This week on IPWatchdog Unleashed, I speak with Martin Correa. Correa, who leads foresight work at the World Intellectual Property Organization (WIPO). Correa’s job is not to predict the future of IP, but to consider what futures are possible so WIPO and Member States can be better prepared for whatever eventuality does materialize. And since there is no data about the future—as he puts it—his work uses signals of change, horizon scanning and competing scenarios to expose assumptions and identify the decisions that could push the IP system in one direction or another.
Recent amendments to Federal Rule of Evidence 702 did not invent the trial judge’s gatekeeping obligation, nor did they transform economic analysis. They did, however, sharpen the focus on the burden of establishing admissibility and whether an expert has reliably applied a valid methodology to the facts. Combined with the Federal Circuit’s increasingly demanding review of patent damages opinions, the practical message is unmistakable: the economic case must be engineered from the beginning, or you will surely suffer the consequences only after it is too late.
In any patent dispute, the strength of the patent still matters. But increasingly, it is not the only thing that matters—or even, in some cases, the thing that matters most. That means where a patent dispute takes place cannot be a tactical afterthought or viewed as a choice of federal district courts in the United States alone. This is true today more than ever because despite patents ostensibly being property—at least according to the Patent Act—which tribunal and which judges make the ultimate decisions affecting the patent often matter most of all because patents and patent enforcement have become driven by ideology and the type of fervor normally reserved highly emotionally charged discussions, like religion and politics.
The U.S. Court of Appeals for the Federal Circuit (CAFC) on Thursday issued a precedential decision affirming a finding of invalidity of certain claims of Satius Holding, LLC’s wireless communications patent, but holding that the district court’s reasoning, which focused on indefiniteness, was erroneous.
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a decision today in Truinject Corp. v. Galderma S.A., affirming a U.S. District Court for the District of Delaware judgment for Galderma S.A. on tortious interference, breach of contract, and trade secret misappropriation claims. The CAFC held that Truinject Corporation forfeited its arguments on appeal about the dismissal of its tortious interference claim and the summary judgment of no damages.
Patent infringement litigation is often discussed in terms of high-profile disputes or headline verdicts. What receives less attention is the cost of getting there. Whether a company is enforcing its patent rights or defending against a claim, the financial impact of patent litigation can be significant long before a case ever reaches trial. For many businesses, particularly those operating in technology-driven industries, patent litigation is no longer just a legal issue. It is a business consideration that can influence strategy, resource allocation and long-term planning.
The mythology surrounding the act of invention tends to concentrate on the breakthrough moment. There is a flash of insight, a sketch is made on a cocktail napkin, the prototype is assembled in a garage to prove the brilliance of the concept. Unfortunately, commercial markets are considerably less romantic. They do not reward ideas merely because they are clever, patentable or even technically superior. They reward products that work, solve a problem customers recognize, can be manufactured at an economically sustainable price and generate an acceptable return for whoever assumes the risk of bringing them to market.
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a decision today in Dental Monitoring SAS v. Align Technology, Inc., affirming a district court ruling that found several patent claims covering deep learning based dental image analysis invalid as directed to ineligible subject matter under Section 101. Dental Monitoring SAS owns U.S. Patent 11,049,248 and U.S. Patent 10,755,409, both of which relate to dental arch image analysis. The ‘248 patent covers “a method for assessing the shape of an orthodontic aligner using a deep learning device,” while the ‘409 patent covers a method for acquiring and analyzing an image of a dental arch using the same type of device.
This week on IPWatchdog Unleashed, IPWatchdog President Renée C. Quinn spoke with Coke Morgan Stewart. Formerly Acting Director and Deputy Director of the U.S. Patent and Trademark Office (USPTO), Stewart is now president and CEO of the Council for Innovation Promotion (C4IP). Their conversation, recorded at IPWatchdog’s 2026 Women’s IP Forum, examines what she learned while leading the agency, why she believes the patent system needs legislative reform, and how her experience has shaped her approach to leadership and advocacy.
This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.
Get Email Updates